Get the Stockscreener App
46.20
2.82%
-1.34
After Hours:
46.33
0.13
+0.28%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $46.20, with a volume of 11.89M.
It is down -2.82% in the last 24 hours and down -0.75% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$47.54
Open:
$47.42
24h Volume:
11.89M
Relative Volume:
0.97
Market Cap:
$94.04B
Revenue:
$47.70B
Net Income/Loss:
$5.07B
P/E Ratio:
18.63
EPS:
2.48
Net Cash Flow:
$14.58B
1W Performance:
-1.99%
1M Performance:
-0.75%
6M Performance:
-22.76%
1Y Performance:
-4.23%
1-Day Range:
$46.19
$47.90
1-Week Range:
$45.85
$48.19
52-Week Range:
$42.96
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
46.20 | 95.97B | 47.70B | 5.07B | 14.58B | 2.48 |
|
LLY
Lilly Eli Co
|
755.39 | 676.48B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.06 | 423.36B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
218.34 | 373.87B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
124.12 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
82.81 | 209.89B | 63.43B | 16.42B | 14.72B | 6.49 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains? - Yahoo Finance
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Stance Capital LLC Purchases 39,165 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Graham Capital Management L.P. Invests $568,000 in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer - Yahoo Finance
Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - GlobeNewswire Inc.
BMO Capital Maintains a Hold on Bristol-Myers Squibb Company (BMY) - Yahoo Finance
October 31st Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold? - Yahoo Finance
Bristol-Myers Squibb (BMY): Assessing Valuation After New Pipeline Updates and Growth Strategy Reveal - Yahoo Finance
Bristol Myers Squibb Company $BMY Shares Acquired by Bayforest Capital Ltd - MarketBeat
Ascent Group LLC Boosts Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
United Services Automobile Association Has $12.60 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Flputnam Lifts Stake in Bristol-Myers Squibb Company (BMY) by 52% - MSN
Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know - Yahoo Finance
BioNTech and Bristol-Myers Squibb Partner to Advance Cancer Therapy - MSN
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC - BioSpace
WCLC25: BioNTech, BMS tout second readout for PD-L1/VEGF-A in SCLC - FirstWord Pharma
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy - Benzinga
BioNTech and Bristol Myers Squibb amend partnership for BNT327 with $1.5 billion upfront payment - Investing.com Canada
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity - The Manila Times
BioNTech, Bristol Myers present interim data from a Phase 2 pumitamig trial - TipRanks
BioNTech and Bristol Myers Squibb Announce Encouraging Phase 2 Data for Pumitamig Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer - Quiver Quantitative
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial - Reuters
BioNTech, BMS tout first global data for PD-L1xVEGF bispecific in small cell lung cancer, set phase 3 dose - Fierce Biotech
Hold Recommendation for Bristol-Myers Squibb Due to Cobenfy’s Modest Growth and Revenue Projections - TipRanks
Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Company $BMY Shares Purchased by Baird Financial Group Inc. - MarketBeat
What is Bristol Myers Squibb Company s debt to equity ratioWeekly Earnings Recap & Free Accurate Trade Setup Notifications - خودرو بانک
Is Bristol-Myers Squibb (BMY) a Value Trap or a Sleeping Giant in Biopharma? - AInvest
Short interest data insights for Bristol Myers Squibb Company Equity RightJuly 2025 Catalysts & High Accuracy Swing Trade Signals - Newser
Using data tools to time your Bristol Myers Squibb Company exitGap Down & Fast Entry and Exit Trade Plans - Newser
Bravehart, a stealthy startup, looks to China to challenge Bristol Myers heart drug - BioPharma Dive
Independent research - Bristol Myers Squibb
Split 3rd Circ. Rejects Janssen, Bristol Myers Pricing Appeal - Law360
Top chart patterns to watch in Bristol Myers Squibb CompanyMarket Growth Summary & AI Driven Stock Price Forecasts - Newser
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga
J&J, Bristol Myers Lose Bid to Revive Suit Over Drug Price Talks - Bloomberg Law News
How Is Bristol-Myers’ Stock Performance Compared To Other Pharma Stocks? - Barchart.com
Canada Pension Plan Investment Board Sells 1,552,813 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: Not As Cheap As It Might Seem (NYSE:BMY) - Seeking Alpha
Gilead starts building manufacturing hub under $32 billion planned US investments - Reuters
Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE? - Yahoo Finance
Combining machine learning predictions for Bristol Myers Squibb CompanyPortfolio Update Report & Expert Curated Trade Ideas - Newser
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
What is Bristol Myers Squibb Company s revenue forecastQuarterly Performance Summary & Reliable Entry Point Trade Alerts - خودرو بانک
Can machine learning forecast Bristol Myers Squibb Company Equity Right recoveryEarnings Recap Report & Technical Confirmation Trade Alerts - Newser
Bristol-Myers Squibb Company (BMY) Launches $300M Immunology Spinout with Bain Capital - MSN
Is it time to cut losses on Bristol Myers Squibb Company Equity RightInsider Buying & Stepwise Trade Signal Guides - Newser
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):